Hidekatsu Nakai

12PUBLICATIONS
94CO-AUTHORS
Predictive and prognostic markersCancer therapy (excl. chemotherapy and radiation therapy)PharmacogenomicsOncology and carcinogenesis not elsewhere classified
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (12)

|Sep 05, 2026
Clinicopathologic features and outcomes of patients with microsatellite instability-high endometrial cancer treated with pembrolizumab in Japan: the KCOG-G1902S/1903S study.

|Dec 22, 2025
Long-term progression-free survivors ("super responders") to olaparib maintenance in recurrent ovarian cancer: a multicenter real-world study (KCOG-G2101s).

Naho Fukuda, Tsuyoshi Takashima, Hidekatsu Nakai

|Sep 09, 2024
Niraparib in Japanese patients with heavily pretreated, homologous recombination-deficient ovarian cancer: final results of a multicenter phase 2 study.

Daisuke Aoki, Tsutomu Tabata, Satoshi Yanagida

|Jul 26, 2024
Niraparib in Japanese patients with platinum-sensitive recurrent ovarian cancer: final results of a multicenter phase 2 study.

Hiroaki Itamochi, Nobuhiro Takeshima, Junzo Hamanishi

|Feb 22, 2023
Histopathological subtyping of high-grade serous ovarian cancer using whole slide imaging.

Chiho Miyagawa, Hidekatsu Nakai, Tomoyuki Otani

|Sep 02, 2021
Nivolumab Versus Gemcitabine or Pegylated Liposomal Doxorubicin for Patients With Platinum-Resistant Ovarian Cancer: Open-Label, Randomized Trial in Japan (NINJA).

Junzo Hamanishi, Nobuhiro Takeshima, Noriyuki Katsumata

Pageof 2

Frequent Collaborators

6 joint publications

Junzo Hamanishi

5 joint publications

Kazuhiro Takehara

5 joint publications

Kosei Hasegawa

4 joint publications

Ajit Suri